Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...219220221222223224225226227228229...10661067»
  • ||||||||||  Rituxan (rituximab) / Roche
    Trial completion, Trial completion date:  A Phase II Study of the FIL on Elderly Frail Patients With DLBCL (clinicaltrials.gov) -  Dec 23, 2022   
    P2,  N=68, Completed, 
    Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Nov 2022
  • ||||||||||  dexamethasone / Generic mfg.
    CHARACTERIZATION OF A NOVEL FKBP51-HSP90 INTERACTION DEFICIENT MOUSE MODEL. (EXHIBITION) -  Dec 23, 2022 - Abstract #ADPD2023ADPD_1856;    
    Behavioral assessment of FKBP5mut mice at 2 -3 months of age indicated lack of behavioral abnormalities at basal conditions. After acute stress FKBP5mut mice exhibited significantly lower levels of corticosterone compared to wild type indicating stress resilience.
  • ||||||||||  dexamethasone / Generic mfg.
    BRIDGING TARGET-ENGAGEMENT AND DISEASE MECHANISM USING MULTI-PARAMETER ANALYSIS OF ALS PATIENT BIOFLUIDS AND HUMAN MODELS. (ONSITE - HALL G3) -  Dec 23, 2022 - Abstract #ADPD2023ADPD_369;    
    Verge PIKfyve inhibitor demonstrated a robust, concentration-dependent inhibition of TLR stimulation response as shown by reduced cytokine release. Conclusions This work highlights a number of markers that are altered in biofluids of ALS patients and that change following PIKfyve kinase inhibition in preclinical models, provides a strong rationale for their use in clinical trials.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  A 'double locked' ratiometric fluorescent probe for detection of cysteine in a viscous system and its application in cancer cells. (Pubmed Central) -  Dec 22, 2022   
    Herein, we have synthesized a 'double locked' probe, acrylic acid 6-[4-(2-benzothiazol-2-yl-2-cyano-vinyl)-phenyl]-naphthalen-2-yl ester (ABN) for the detection of Cys in a viscous medium and explored its application to living cells that were exposed to dexamethasone to regulate the intracellular viscosity level...A turn-on fluorescence signal was visualized when the probe was individually treated with Cys and glycerol (a standard viscosity source). Therefore, we propose that ABN is a fluorescent probe that permits the monitoring of variations in intracellular viscosity and Cys levels in a biological environment, and it can be utilized in innumerable cellular damage models.
  • ||||||||||  Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
    Journal:  Risankizumab (Skyrizi) - An IL-23 antagonist for Crohn's disease. (Pubmed Central) -  Dec 22, 2022   
    Both formulations were well tolerated and demonstrated clinically meaningful and sustained improvements in vision and retinal thickening in patients with retinal vein occlusion with longstanding edema. No abstract available
  • ||||||||||  prednisolone / Generic mfg.
    Journal:  Bullous Pemphigoid in X-linked Alport Syndrome: A Case Report. (Pubmed Central) -  Dec 22, 2022   
    Oral prednisolone improved his symptoms gradually. Abundant tense blisters on the palms and soles might suggest an important role of the α5 (IV) chain in the integrity of BMZ.
  • ||||||||||  Olumiant (baricitinib) / Incyte, Eli Lilly, Actemra IV (tocilizumab) / Roche, JW Pharma
    Review, Journal:  How We Have Treated Severe to Critically Ill Patients With Coronavirus Disease 2019 in Korea. (Pubmed Central) -  Dec 21, 2022   
    In addition, venous thromboembolism prophylaxis is one of the important adjunctive therapies for patients with severe COVID-19. In the clinical field, treatment of severely ill patients with COVID-19 based on guidelines is widely practiced by medical staff and established currently.
  • ||||||||||  dexamethasone / Generic mfg.
    Retrospective data, Journal:  Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis. (Pubmed Central) -  Dec 21, 2022   
    However, in patients with non-severe COVID-19, the use of corticosteroids did not decrease all-cause mortality and may prolong the duration of hospital stay. In addition, we revealed that a low dose of dexamethasone with a long treatment course could reduce all-cause mortality in COVID-19 patients.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection. (Pubmed Central) -  Dec 21, 2022   
    Preliminary data from Recovery clinical trial raises hope by showing that treatment with dexamethasone at doses of 6 mg/day shows a reduction on morbidity in patients requiring added oxygen therapy...Multivariate analysis shows that age, dyspnea and C-reactive protein are markers of hospital discharge with an area below the curve of 0.816. In patients with methylprednisolone pulses, the capacity of the predictive model for hospital discharge including variables collected at 5 days was (area under the curve) 0.816.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Topical phenylbutyrate antagonizes NF-κB signaling and resolves corneal inflammation. (Pubmed Central) -  Dec 21, 2022   
    More importantly, PBA can synergize with the dexamethasone to antagonize NF-κB signaling at lower drug concentrations. Our results demonstrate that PBA therapy exerts previously unreported anti-inflammatory effects in the eye and facilitates corneal healing during persistent inflammation.
  • ||||||||||  dexamethasone / Generic mfg.
    Biomarker, Journal:  Pharmacogenomic markers of glucocorticoid response in congenital adrenal hyperplasia. (Pubmed Central) -  Dec 21, 2022   
    GR genotype-phenotype associations were explored after a dexamethasone suppression test using very low-doses (VLD-DST), 20 and 40 μg/m²...The Tth111I + 9β/ Wild or Tth111I + ER22/23EK + 9β/ Wild genotypes were associated to GC resistance in this population. This finding may be relevant given the challenges posed by therapeutic management with GC in CAH.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Overcoming apoptotic resistance afforded by Bcl-2 in lymphoid tumor cells: a critical role for dexamethasone. (Pubmed Central) -  Dec 21, 2022   
    Extending our study using other potassium ionophores revealed that direct depolarization of the mitochondria membrane potential coupled with prior treatment with glucocorticoids is the key mechanism for activating the cell death program and bypassing the resistance afforded by Bcl-2 in lymphoid cells. Finally, we show that the duration of dexamethasone pre-treatment is critical for regulating distinct genes and signaling pathways that sensitize the cells to die.
  • ||||||||||  Yutiq (fluocinolone acetonide intravitreal implant) / EyePoint Pharma
    Enrollment closed, Enrollment change, Trial primary completion date:  Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI) (clinicaltrials.gov) -  Dec 21, 2022   
    P3,  N=12, Active, not recruiting, 
    Trial completion date: Nov 2021 --> Nov 2023 | Trial primary completion date: Nov 2021 --> Nov 2023 Recruiting --> Active, not recruiting | N=60 --> 12 | Trial primary completion date: Oct 2022 --> Apr 2023
  • ||||||||||  dronabinol oral / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  PrECEPT: Effects of Pregnancy-associated Hormones on THC Metabolism in Women (clinicaltrials.gov) -  Dec 21, 2022   
    P4,  N=12, Active, not recruiting, 
    Recruiting --> Active, not recruiting | N=60 --> 12 | Trial primary completion date: Oct 2022 --> Apr 2023 Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: May 2023 --> Dec 2023
  • ||||||||||  Darzalex Faspro (daratumumab and hyaluronidase-fihj) / J&J
    Enrollment closed, Enrollment change, Combination therapy:  Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab (clinicaltrials.gov) -  Dec 21, 2022   
    P2,  N=88, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: May 2023 --> Dec 2023 Recruiting --> Active, not recruiting | N=230 --> 88
  • ||||||||||  hydrocortisone / Generic mfg., nystatin oral / Generic mfg.
    Journal:  Development and Evaluation of Combined Effect Buccal Films for Treatment of Oral Candidiasis. (Pubmed Central) -  Dec 21, 2022   
    Consequently, XT-O2 formulation that was prepared with xanthan gum and tween 80, was best for its highest antifungal film activity (20.00 ± 0.07 mm), released nystatin (44.296% ± 1.695), and lowest erosion matrix (36.719% ± 0.249). The selected formulation can be used for compatibility, stability and in vivo studies targeted oral candidiasis infections.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  CO fractional laser combined with triamcinolone acetonide injection for the hypertrophic scars: which is first? (Pubmed Central) -  Dec 21, 2022   
    Before treatment, there was no difference in scar thickness and VSS score between the two groups (P > 0.05). After treatment, the above indexes in CO FL-TA group were significantly better than those in TA-CO FL group (P < 0.05); the incidence of adverse reactions in CO FL-TA group was 9.38%, which was significantly lower than that in TA-CO FL group (18.75%) (P < 0.05); the total effective rate of CO FL-TA group was 90.63%, which was significantly higher than that in TA-CO FL group (65.63%) (P < 0.05). In the process of combined CO fractional laser and triamcinolone acetonide injection in the treatment of hypertrophic scars, CO fractional laser treatment first, and then triamcinolone acetonide injection can reduce the number of treatments, reduce the incidence of adverse reactions, and achieve more satisfactory treatment effect.
  • ||||||||||  hydrocortisone / Generic mfg.
    Journal:  CircHIPK3 promotes bone microvascular endothelial cell proliferation, migration and angiogenesis by targeting miR-7 and KLF4/VEGF signaling in steroid-induced osteonecrosis of the femoral head. (Pubmed Central) -  Dec 20, 2022   
    After treatment, the above indexes in CO FL-TA group were significantly better than those in TA-CO FL group (P < 0.05); the incidence of adverse reactions in CO FL-TA group was 9.38%, which was significantly lower than that in TA-CO FL group (18.75%) (P < 0.05); the total effective rate of CO FL-TA group was 90.63%, which was significantly higher than that in TA-CO FL group (65.63%) (P < 0.05). In the process of combined CO fractional laser and triamcinolone acetonide injection in the treatment of hypertrophic scars, CO fractional laser treatment first, and then triamcinolone acetonide injection can reduce the number of treatments, reduce the incidence of adverse reactions, and achieve more satisfactory treatment effect. The circHIPK3 promotes BMEC proliferation, migration and angiogenesis by targeting miR-7 and KLF4/VEGF signaling.